Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis - Report - MDSpire

Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis

  • By

  • Yan Wang

  • Xiaoyan Wang

  • Guihong Yu

  • Libao Zhang

  • Changhui Xue

  • Wanchen Gong

  • Jiashou Luo

  • Chengwu Lu

  • Linfeng Wang

  • July 9, 2026

  • 0 min

Share

Clinical Report: Comparative Analysis of Abaloparatide, Denosumab, Teriparatide

Overview

This systematic review and Bayesian network meta-analysis evaluates the efficacy and safety of abaloparatide, denosumab, teriparatide, and bisphosphonates in treating postmenopausal osteoporosis.

Background

Postmenopausal osteoporosis is a significant health concern, leading to increased fracture risk and impacting quality of life. Effective management of this condition involves pharmacological interventions that vary in their mechanisms and outcomes.

Data Highlights

AgentEffect on Lumbar Spine BMDEffect on Femoral Neck BMDEffect on Total Hip BMDRisk of AEsRisk of SAEs
Abaloparatide (ABA)Greatest improvementSecond greatest improvementHighest effectLowLow
Teriparatide (TER)Second greatest improvementGreatest improvementModerateLowest riskModerate
Denosumab (DEN)Moderate benefitsModerate benefitsModerateModerate riskModerate
Oral Bisphosphonates (OBP)Moderate benefitsModerate benefitsModerateLowest riskModerate
Intravenous Bisphosphonates (IBP)Moderate benefitsModerate benefitsModerateModerate riskModerate
Placebo/Conventional Therapy (PLA/CTRL)LowestLowestLowestModerate riskLow

Key Findings

  • Abaloparatide showed the greatest improvement in lumbar spine and femoral neck BMD.
  • Teriparatide was effective in improving femoral neck BMD.
  • Denosumab and bisphosphonates provided moderate benefits compared to placebo.
  • Abaloparatide had the highest effect on total hip BMD.
  • Teriparatide and oral bisphosphonates exhibited the lowest risk for adverse events.

Clinical Implications

The favorable safety profiles of these agents may influence treatment decisions in high-risk patients.

Conclusion

Abaloparatide and teriparatide are effective treatments for enhancing bone mineral density in postmenopausal osteoporosis.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Author(s)/Org, Source, Year -- Title
  6. Author(s)/Org, Source, Year -- Title
  7. Author(s)/Org, Source, Year -- Title
  8. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians - PMC
  9. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis | New England Journal of Medicine
  10. Osteoporosis International (2025) 36:951–967

Original Source(s)

Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis

  • by Yan Wang, Xiaoyan Wang, Guihong Yu, Libao Zhang, Changhui Xue, Wanchen Gong, Jiashou Luo, Chengwu Lu, Linfeng Wang

  • July 9, 2026

Related Content

Associations of parathyroid hormone and atrial fibrillation: epidemiological insights from the LURIC study

Another big premium hike on the horizon

The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process